Multiple Myeloma Articles

Expert Highlights Evolving Approaches for Newly Diagnosed Multiple Myeloma
Prashant Kapoor, MD, discusses the importance of minimal residual disease negativity, using International Myeloma Working Group criteria, and field-changing pivotal data in multiple myeloma.
Kumar Recaps Ongoing Advances in Myeloma
Shaji Kumar, MD, discusses novel therapies for patients with multiple myeloma in detail, the sequencing challenges ahead, and which current agents pose the greatest challenge.
Next Steps in Myeloma Include Combo Regimens and Achieving MRD
Ruben Niesvizky, MD, discusses some of the exciting advances, the potential of chimeric antigen receptor T-cell therapy, and emerging combination regimens on the horizon in multiple myeloma.
EU Approves Daratumumab Triplets for Myeloma
The European Commission has approved daratumumab for use in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for the treatment of patients with multiple myeloma following at least 1 prior therapy.
Kite Unveils Novel BCMA-Directed CAR T-cell Therapy
A novel target, B-cell maturation antigen, has been identified for future therapeutic development as chimeric antigen receptor T-cell therapy for patients with multiple myeloma.
Consolidation Approach Extends PFS in Multiple Myeloma
Consolidation therapy with lenalidomide, bortezomib, and dexamethasone (RVD), when used in conjunction with stem cell transplantation, extended progression-free survival compared with RVD alone in patients with multiple myeloma.
Guideline Emphasizes Emotional, Physical Needs of Myeloma Patients
There is no comprehensive, multidisciplinary guideline document for the screening, management, and long-term care of myeloma patients. The UK Myeloma Forum and the British Society for Haematology set out to address this need and published such a guideline in a recent issue of the British Journal of Hematology.
Beyond Myeloma: New Roles for IMiDs
The past several decades have witnessed a dramatic improvement in the treatment of patients with multiple myeloma, the second most common type of hematologic malignancy. A better understanding of the biology of this disease and the introduction of a wealth of novel drug classes has more than doubled median survival times. 
A supplemental biologics license application has been submitted to the FDA for the use of denosumab for the prevention of skeletal-related events in patients with multiple myeloma.
Lonial Discusses Dramatic Progress in Multiple Myeloma
Sagar Lonial, MD, discusses recent advances that have revolutionized the treatment of patients with multiple myeloma.
 
Publication Bottom Border
Border Publication